000 witnessed up to 180.

Practice guidelines for after the first UTI in children recommend an imaging study of the presence and degree of VUR; evaluate a condition 30 to 40 % 30 to 40 % of children with UTI. When the child VUR, daily antibiotic treatment in an attempt to prevent recurrent urinary tract infections recommended. Evidence is limited regarding risk factors for recurrent urinary tract infections and the risks and benefits of treatment with antibiotics..

Grade 1 to 3 VUR, and other antibiotic exposure had no effect on the risk of recurrent UTI. Exposure to prophylactic antibiotics significantly increased the likelihood of resistant infections . ‘Showed Given previous findings and the unfavorable risk / benefit ratio of the current study, we believe it is prudent for clinicians to discuss the risks and unclear benefits of prophylaxis with make make family – centered decisions not to start if prophylactic[ antibiotics] to monitor or just a child without prescription[ antibiotic] prophylaxis after a first UTI, ‘the authors write..Elbit Imaging Ltd. , announced that their subsidiary, InSightec Ltd. Admitted that Japan’s the Ministry of Health, Labour and Welfare the company has allowed the ExAblate MR-guided focused ultrasonic for the treatment of women with uterine fibroids.

Activities Elbit Imaging Ltd. Is into to following major areas divided mixed use property projects, mostly in the retail sector and in Central & Eastern Europe and India, hotels – hotels ownership, operation, management and selling, mainly to major European cities, Image Guided Treatment – investing in research and development of, production and sale of magnetic resonance guided focused ultrasonic treatment equipment, residential initiation initiation, constructing and selling residential projects and others mixed-use real projects, predominantly residential, in East Europe and in India and Other activity – The distribution and marketing of fashion clothing and accessories in of Israel; venture capital investments, under the headline but are statements are not to in hospitals and courtyard and dairies in India, which are in the precursor.

ExAblate is the only non-invasive treatment for uterine fibroids permitted for use in Japan.

Dudi Machluf, Chief Executive Officer of Elbit Imaging, said:’InSightec is technological is the first non-invasive treatment for uterine fibroids for the use of the Japanese Ministry of Health, Labour and Welfare approval, a power which speaks for itself.